Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
ABVX
ABVX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ABVX News
Abivax Under Investigation Following Phase 3 Trial Results, Shares Plummet
Jun 11 2026
PRnewswire
Abivax Under Investigation for Securities Violations Amid Trial Results
Jun 10 2026
Globenewswire
Abivax Under Investigation Following Phase 3 Trial Results, Shares Plummet
Jun 08 2026
PRnewswire
ABIVAX and Others See Significant Stock Gains
Jun 04 2026
NASDAQ.COM
Abivax's Drug Trial Data Triggers Stock Volatility
Jun 03 2026
Fool
Abivax's Drug Development Progress and Market Reaction
Jun 03 2026
NASDAQ.COM
Jefferies Downgrades Abivax Amid Cancer Concerns
Jun 03 2026
PRnewswire
Abivax Shares Plunge 44% Following Cancer Cases in Trial
Jun 03 2026
Newsfilter
Abivax Shares Plunge 44% as Analysts Cut Price Targets Following Trial Data
Jun 03 2026
stocktwits
Jefferies Downgrades Abivax Amid Cancer Signal Concerns
Jun 02 2026
stocktwits
Abivax Drug Trial Results Mixed Despite Positive Efficacy
Jun 02 2026
seekingalpha
Abivax Shares Plunge 32% Amid Cancer Risk Concerns
Jun 02 2026
Newsfilter
Abivax Reports Landmark Phase 3 Trial Results for Obefazimod in Ulcerative Colitis
Jun 02 2026
NASDAQ.COM
European Equities Rebound as Investors Await Key Economic Data
Jun 02 2026
CNBC
Abivax Shares Plunge 32% Following New Drug Data Release
Jun 02 2026
CNBC
Abivax's Ulcerative Colitis Drug Trial Results Cause Stock Volatility
Jun 01 2026
stocktwits
Show More News
